These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20721555)

  • 1. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
    Zappasodi P; Rossi M; Ambaglio I; Bernasconi P; Corso A; Lazzarino M; Castagnola C
    Ann Hematol; 2011 May; 90(5):595-7. PubMed ID: 20721555
    [No Abstract]   [Full Text] [Related]  

  • 2. Unusual manifestations of acute leukemia. Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission.
    Au WY; Ma SK; Ooi C; Liang R; Kwong YL
    J Clin Oncol; 2000 Oct; 18(19):3435-7. PubMed ID: 11013284
    [No Abstract]   [Full Text] [Related]  

  • 3. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic-induced APL differentiation in cerebrospinal fluid.
    Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
    Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
    Au WY; Tam S; Fong BM; Kwong YL
    Blood; 2006 Apr; 107(7):3012-3. PubMed ID: 16554490
    [No Abstract]   [Full Text] [Related]  

  • 6. Arsenic trioxide entered cerebrospinal fluid with the help of mannitol overwhelm the meningeal relapse of acute promyelocytic leukemia.
    Jin Z; Ran M; Man Z
    Haematologica; 2007 Sep; 92(9):e82-4. PubMed ID: 17768137
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
    Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
    Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lo Coco F
    Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655
    [No Abstract]   [Full Text] [Related]  

  • 9. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E; Schultheis B; Büchner T; Hehlmann R
    Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
    Powell BL
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1317-9. PubMed ID: 21929304
    [No Abstract]   [Full Text] [Related]  

  • 13. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 14. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
    Au WY; Tam S; Kwong YL
    Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
    [No Abstract]   [Full Text] [Related]  

  • 15. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
    Kiguchi T; Yoshino Y; Yuan B; Yoshizawa S; Kitahara T; Akahane D; Gotoh M; Kaise T; Toyoda H; Ohyashiki K
    Leuk Res; 2010 Mar; 34(3):403-5. PubMed ID: 19733394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
    Tallman MS
    Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-time quantification of the multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide.
    Au WY; Chim CS; Wai Lie AK; Pang A; Kwong YL
    Haematologica; 2002 Oct; 87(10):1109-11. PubMed ID: 12368167
    [No Abstract]   [Full Text] [Related]  

  • 18. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
    Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
    Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
    Zhang P
    J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Arsenic trioxide as a therapeutic agent in APL].
    Emi N
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():724-8. PubMed ID: 17474483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.